Plant Name: Alstonia yunnanensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.907E-12 | 8.608E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.600E-10 | 1.272E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.716E-09 | 7.393E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.282E-08 | 1.126E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.120E-08 | 1.360E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.678E-08 | 1.360E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.445E-08 | 1.469E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-07 | 1.905E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.876E-07 | 3.132E-04 | ALOX12, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| CC | Unclassified; | GO:0120111; neuron projection cytoplasm | 3.238E-07 | 3.358E-04 | HIF1A, MAPK1, MAPT, OPRM1 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.900E-07 | 3.860E-04 | HIF1A, MAPK1, MAPT, OPRM1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.942E-07 | 8.466E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.455E-06 | 1.980E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, HSD11B1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.993E-06 | 2.805E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0071242; cellular response to ammonium ion | 5.176E-06 | 3.315E-03 | CASP7, MAPK1, OPRM1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.097E-05 | 5.973E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, HSD11B1, PTGES, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.718E-05 | 8.500E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.017E-09 | 2.239E-07 | CYP2C9; ALOX12; CYP2C19; PTGES; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.412E-09 | 3.979E-07 | HSD11B1; CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.069E-08 | 1.129E-06 | CYP2C9; MAPK1; ALOX12; CYP2C19; PTGS1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.075E-08 | 3.979E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.827E-07 | 8.496E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.808E-07 | 8.894E-06 | HSD11B1; CYP2C9; CYP1A2; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.303E-06 | 8.409E-05 | HSD11B1; CYP2C9; CYP1A2; ALOX12; CYP2C19; CYP3A4; PTGS1; PTGES |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.582E-05 | 3.184E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.831E-05 | 2.541E-04 | HSD11B1; CYP1A2; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.969E-05 | 4.406E-04 | CASP7; CASP1; MAPK1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.330E-04 | 4.369E-03 | CASP7; MAPK1; MAPT |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.104E-03 | 1.012E-02 | CASP7; CASP1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.313E-03 | 1.041E-02 | MAPK1; HIF1A |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.586E-03 | 1.134E-02 | MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.186E-03 | 1.012E-02 | CASP1; MAPK1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.634E-03 | 1.134E-02 | MAPK1; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.989E-03 | 1.226E-02 | PTPN1; MAPK1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.524E-03 | 1.921E-02 | MAPK1; OPRM1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.832E-03 | 1.196E-02 | ABCB1; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.665E-03 | 1.921E-02 | MAPK1; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.330E-03 | 2.078E-02 | CASP7; MAPK1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.808E-03 | 1.921E-02 | MAPK1; HIF1A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.674E-03 | 1.562E-02 | CASP1; MAPK1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.297E-03 | 2.261E-02 | MAPK1; PTGS1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.965E-03 | 2.204E-02 | MAPK1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.916E-03 | 2.742E-02 | CASP7; MAPK1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.062E-02 | 4.066E-02 | CASP1; MAPK1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.821E-03 | 2.742E-02 | PTPN1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.492E-03 | 2.078E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1 |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; HSD11B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; MAPK1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; OPRM1; OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | OPRM1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; OPRM1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; OPRM1; HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRM1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGES; MAPT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; HIF1A; MAPK1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | OPRM1; OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRM1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; OPRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |